Assessment of the Safety and Effectiveness of CD38-Targeted CAR-T Cell Therapy in Treating Multiple Myeloma: A Systematic Review and Meta-Analysis - Takeaways - MDSpire

Assessment of the Safety and Effectiveness of CD38-Targeted CAR-T Cell Therapy in Treating Multiple Myeloma: A Systematic Review and Meta-Analysis

  • By

  • Xinlong Xu

  • Chang Dong

  • Jiashuo Guo

  • Xiaolin Chang

  • Yu Zhang

  • Shuting Gou

  • Liying Xue

  • Jie Li

  • April 29, 2026

  • 0 min

Share

  • 1

    CD38-targeted CAR-T therapy shows promising efficacy in treating relapsed/refractory multiple myeloma, particularly with dual-target constructs.

  • 2

    The pooled overall response rate for dual-target CD38/BCMA CAR-T was 89%, with a complete response rate of 63%.

  • 3

    Single-target CD38 CAR-T therapy demonstrated lower efficacy, with an overall response rate of only 33% and higher mortality at 44%.

  • 4

    Cytokine release syndrome occurred in 83% of patients receiving CAR-T therapy, with 26% experiencing grade ≥3 severity.

  • 5

    Further large-scale studies are needed to clarify the optimal role of CD38-directed CAR-T therapy in the treatment of multiple myeloma.

Original Source(s)

Assessment of the Safety and Effectiveness of CD38-Targeted CAR-T Cell Therapy in Treating Multiple Myeloma: A Systematic Review and Meta-Analysis

  • by Xinlong Xu, Chang Dong, Jiashuo Guo, Xiaolin Chang, Yu Zhang, Shuting Gou, Liying Xue, Jie Li

  • April 29, 2026

Related Content

Case Report: First description of an intracranial “NET” in ROHHAD syndrome; time to rename to the ROHHAD-NeCT syndrome?

Bilateral renal metastasis following radical prostatectomy for prostate cancer: a case report

Impact of the clonal architecture and probable biallelic inactivation of TET2 mutations in myelodysplastic neoplasms